Atrasentan (Vanrafia) was approved in 2025 for the treatment of IgAN in people who are at risk of their disease getting worse quickly. It belongs to a class of medicines called endothelin receptor ...

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed ...

The drug, known as atrasentan and sold as Vanrafia, blocks a specific protein in the kidneys known as endothelin A (ETA) receptor, which causes inflammation and cellular damage leading to proteinuria.

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Novartis’ Vanrafia, a treatment aimed at decreasing proteinuria in adults with primary immunoglobulin A nephropathy ...

Novartis stock popped Thursday — prompting rival Travere Therapeutics to slide — after winning Food and Drug Administration approval for a kidney disease treatment. Late Wednesday, the FDA ...

Bearing the commercial moniker Vanrafia, the selective endothelin A receptor antagonist (ERA) does not have to be used under an FDA-mandated safety-related program called REMS. A sans-REMS FDA ...

Basel, April 3, 2025 – Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia ® (atrasentan), a potent and selective endothelin A (ETA ...